LLY LLY
Eli Lilly Anticipates Key Readouts for Obesity and Alzheimer's Drugs in H1 2026
Eli Lilly faces a significant period in the first half of 2026, driven by two major clinical milestones. Both events are scheduled for March. The first...
Eli Lilly Upgraded to Strong-Buy by Zacks Research
Zacks Research upgraded Eli Lilly and Company (LLY) on January 3, 2026. The rating moved from "hold" to a "strong-buy." This improved rating reflects a...
Eli Lilly Completes Sale of New Jersey Manufacturing Facility to Celltrion
Eli Lilly and Company finalized the sale of its biopharmaceutical production facility in Branchburg, New Jersey, to South Korea-based Celltrion. Celltrion...
Eli Lilly and Other Drugmakers Announce 2026 Price Increases
Eli Lilly & Co. and several other drugmakers plan to raise U.S. prices on certain medicines starting in January 2026. The reported median price hike across...
Eli Lilly Sees Certain Fraud Claims Trimmed in Insulin-Pricing Lawsuit
The U.S. District Court for the District of New Jersey dismissed certain civil fraud claims against Eli Lilly & Co. and other drugmakers. The claims related to...
Eli Lilly and Boehringer Ingelheim to Cut Jardiance Price by Over 40%
Eli Lilly and partner Boehringer Ingelheim will cut the U.S. list price of the diabetes drug Jardiance and related treatments. The reduction exceeds 40%. This...
Eli Lilly and Partner Vanda Pharmaceuticals Gain FDA Approval for Novel Motion Sickness Drug
Eli Lilly and Vanda Pharmaceuticals secured FDA approval for Nereus (tradipitant). The drug is indicated for the prevention of vomiting induced by...
Eli Lilly Slashes Mounjaro Prices in China Amidst Growing Competition
Eli Lilly and Company implemented a significant price reduction for its popular weight-loss drug, Mounjaro, in the Chinese market. Reports citing Chinese drug...
Eli Lilly Implements Previously Announced Price Reductions for Mounjaro and Zepbound in Canada
Eli Lilly and Company implemented a significant price reduction for its diabetes and weight-loss drugs, Mounjaro and Zepbound, in the Canadian market. The...
Eli Lilly CEO David Ricks Named 'Newsmaker of the Year' Amidst Company's Landmark 2025 Performance
Eli Lilly CEO David Ricks was named the Indianapolis Business Journal's 'Newsmaker of the Year' for the fourth consecutive time. The recognition highlights the...
Eli Lilly Invests $55 Million in South Korean Biotech ABL Bio
Eli Lilly committed $55 million to South Korean biotechnology firm ABL Bio. The investment includes a $40 million upfront payment and a $15 million equity...
Eli Lilly Faces Enhanced Oral Weight-Loss Competition as Novo Nordisk Secures First FDA Approval
Novo Nordisk secured U.S. FDA approval for its oral Wegovy on December 23, positioning it as the first oral weight-loss GLP-1 drug on the market. This...
Lilly's Cancer Drug Inluriyo Gains Companion Diagnostic Approval in Japan
Guardant Health Japan, a partner of Eli Lilly, secured approval from Japanese regulators for the Guardant360 CDx genomic profiling panel. The panel functions...
Eli Lilly Reinforces Commitment to ESG Principles as a Core Business Strategy
Eli Lilly and Company integrates Environmental, Social, and Governance (ESG) principles directly into its core business strategy. Jim Greffet, Lilly's head of...
Eli Lilly Previews 2026 JP Morgan Conference Strategy, Focusing on GLP-1 Supply and Growth
Eli Lilly and Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company plans to address previous supply...
Eli Lilly's Potential Abivax Takeover Speculation Intensifies
Speculation regarding a potential takeover of French biotech Abivax by Eli Lilly intensified on December 22, 2025. Fresh reports allege that Eli Lilly...
Eli Lilly Partners with Korean Startup MEDI&GENE on Next-Generation Obesity Drug
Eli Lilly and Company has partnered with South Korean biopharmaceutical startup MEDI&GENE to jointly advance a next-generation therapeutic candidate for...
🟢 LLY is trading 3% up today on positive Phase 3 data for oral drug orforglipron
LLY is trading at +3.06% now at $1073.65 following the announcement of positive Phase 3 trial results for its oral weight-loss drug, orforglipron. * The...
Eli Lilly Slashes Prices for Mounjaro and Zepbound in Canada by Over 20%
Eli Lilly will cut prices on its popular drugs Mounjaro (diabetes) and Zepbound (weight-loss) in Canada by 20% or more, according to a report from The Globe...
Eli Lilly edges lower in after-hours trading amid rotation analysis versus Nvidia
Eli Lilly shares saw a mild pullback of -1.21% during the regular session, trading slightly lower in after-hours around $1,040, as a MarketWatch/Dow Jones...